Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 15/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 4/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.44 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803947 | 0.92 | PTGER1 (0.48) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL8161439 | 0.91 | PTGER1 (0.46) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL8168635 | 0.91 | PTGER1 (0.48) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL9055421 | 0.90 | PTGER1 (0.46) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL8167536 | 0.88 | USP28 (0.46) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL8162300 | 0.87 | PTGER1 (0.51) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL7662551 | 0.87 | HPGD (0.42) | PTGER1CYP1A2 | |
| SCHEMBL8154853 | 0.86 | PTGER1 (0.46) | PTGER1CYP1A2CCR5USP28USP25 | |
| SCHEMBL8167308 | 0.86 | PTGER1 (0.54) | PTGER1CYP1A2CCR5 | |
| SCHEMBL8167529 | 0.86 | PTGER1 (0.45) | PTGER1CYP1A2CCR5USP28USP25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102524-A1 | Method of treatment | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | claimed |
| EP-1370266-A1 | METHOD OF TREATMENT | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| US-20030114459-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | claimed |
| US-6537991-B1 | Method of treating a peripheral neuropathic pain | ASTRAZENECA AB (SE) | 2003-03-25 | — | — | US | claimed |
| JP-2002537233-A | — | — | 2002-11-05 | — | — | JP | claimed |
| WO-2002072098-A1 | METHOD OF TREATMENT | ASTRAZENECA AB (SE) | 2002-09-19 | — | — | WO | claimed |
| CN-1085663-C | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2002-05-29 | — | — | CN | claimed |
| EP-1154773-A2 | USE OF ANTAGONISTS OF PG-E FOR THE TREATMENT OF NEUROPATHIC PAIN | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | claimed |
| EP-0773930-B1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LTD (GB) | 2000-10-11 | — | — | EP | claimed |
| WO-2000048446-A2 | USE OF ANTAGONISTS OF PG-E FOR THE TREATMENT OF NEUROPATHIC PAIN | ASTRAZENECA AB (SE) | 2000-08-24 | — | — | WO | claimed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | claimed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | claimed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | claimed |
| US-8076315-B2 | In conjunction with serotonin receptor agonists, serotonin receptor antagonists, cannabinoid receptor agonists, serotonin reuptake inhibitors, noradrenalin reuptake inhibitors, endocannabinoid promoters, antagonists of cannabinoid membrane transporters, antagonists of cannabinoid degradative enzymes | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080261922-A1 | Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists | THE BOARD OF TRUSTEES OF THE UNIVERISTY OF ILLINOIS | 2008-10-23 | — | — | US | disclosed |
| WO-2007047372-A2 | PHARMACOLOGICAL TREATMENTS FOR SLEEP DISORDERS (APNOE) WITH PROSTANOID RECEPTOR ANTAGONISTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2000048446-A2 | USE OF ANTAGONISTS OF PG-E FOR THE TREATMENT OF NEUROPATHIC PAIN | ASTRAZENECA AB (SE) | 2000-08-24 | — | — | WO | disclosed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | disclosed |
| EP-0773930-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003380-A1 | AROMATIC AMINO ETHERS AS PAIN RELIEVING AGENTS | ZENECA LIMITED (GB) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102524-A1 | Method of treatment | PTGER1, PTGS1, PTGER2 | PTGER1 1/4885CYP1A2 1298/4885CCR5 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.